Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011–2012 season
Article first published online: 19 AUG 2013
© 2013 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Influenza and Other Respiratory Viruses
Volume 8, Issue 2, pages 151–158, March 2014
How to Cite
2013) Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A (H3N2) and B in the 2011–2012 season. Influenza and Other Respiratory Viruses 8(2), 151–158.et al. (
- Issue published online: 26 FEB 2014
- Article first published online: 19 AUG 2013
- Manuscript Accepted: 30 JUN 2013
- Grant-in-Aid for Scientific Research (C). Grant Number: 22591174
- Ministry of Education, Science, Sports and Culture of Japan
- Global COE Program
- GlaxoSmithKline, Inc.
- Meiji Seika Pharma Co., Ltd
- Biphasic fever;
- laninamivir octanoate;
- neuraminidase inhibitors;
To evaluate the clinical effectiveness of the two inhaled neuraminidase inhibitors (NAIs), zanamivir (ZN) and laninamivir octate (LO), for influenza A(H3N2) and B virus infections.
A prospective, multicenter observational study was conducted from January to April in 2012.
Outpatients aged 5–18 years who had a temperature of 37.5°C or higher and were diagnosed as having influenza based on an immunochromatographic assay were enrolled.
A total of 338 patients treated with ZN and 314 patients treated with LO were compared.
Main outcome measures
The duration of fever after administration of the first dose of each NAI was evaluated as a primary endpoint. The secondary endpoint was episodes of biphasic fever.
No statistically significant difference in the duration of fever was found between the ZN and LO groups (log-rank test, P = 0.117). A logistic regression model showed that episodes of biphasic fever increased by 1.19 times for every decrease of 1 year of age (P = 0.016) and that the number of biphasic fever episodes in patients treated with LO was 5.80-times greater than that in patients treated with ZN (P < 0.001).
Although the duration of fever in the LO group was comparable to that in the ZN group, episodes of biphasic fever were more frequent in younger children and in the LO group than in the ZN group.